The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2023 | Bispecifics & CAR-T therapy in DLBCL: sequencing and selecting between these agents
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, shares some insights into the sequencing of immunotherapies in diffuse large B-cell lymphoma (DLBCL). Prof. Jäger explains that bispecific antibodies are likely to move into the first-line setting for patients with high-risk disease, and further comments on the importance of bispecifics as a treatment option for patients who relapse after CAR-T therapy. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
